Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Merck
Dow
Johnson and Johnson
Moodys
McKinsey
AstraZeneca

Last Updated: June 26, 2022

CLINICAL TRIALS PROFILE FOR ATROPINE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Atropine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000170 ↗ Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia Completed National Eye Institute (NEI) Phase 3 1999-04-01 - To determine whether the success rate with drug treatment (atropine) of amblyopia due to strabismus or anisometropia in patients less than 7 years old is equivalent to the success rate with occlusion (patching) therapy - To develop more precise estimates of the success rates of amblyopia treatment - To identify factors that may be associated with successful treatment of amblyopia - To collect data on the course of treated amblyopia to provide more precise estimates of treatment effects than are now available Extended Follow up of Study Patients - Primary: To determine the long-term visual acuity outcome at age 10 years and at age 15 years in patients diagnosed with amblyopia before age 7 years. - Secondary: To determine whether the long-term visual acuity outcome at age 10 years and at age 15 years differs between patients who received patching followed by best clinical care and patients who received atropine followed by best clinical care
NCT00000170 ↗ Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia Completed Jaeb Center for Health Research Phase 3 1999-04-01 - To determine whether the success rate with drug treatment (atropine) of amblyopia due to strabismus or anisometropia in patients less than 7 years old is equivalent to the success rate with occlusion (patching) therapy - To develop more precise estimates of the success rates of amblyopia treatment - To identify factors that may be associated with successful treatment of amblyopia - To collect data on the course of treated amblyopia to provide more precise estimates of treatment effects than are now available Extended Follow up of Study Patients - Primary: To determine the long-term visual acuity outcome at age 10 years and at age 15 years in patients diagnosed with amblyopia before age 7 years. - Secondary: To determine whether the long-term visual acuity outcome at age 10 years and at age 15 years differs between patients who received patching followed by best clinical care and patients who received atropine followed by best clinical care
NCT00000333 ↗ Evaluation of Benztropine for Cocaine Craving - 2 Completed Washington D.C. Veterans Affairs Medical Center Phase 2 2001-05-01 The purpose of this study is to compare the efficacy of benztropine (or DA reuptake inhibitor) with atropine and placebo in affecting stimulated craving to cocaine cues.
NCT00000333 ↗ Evaluation of Benztropine for Cocaine Craving - 2 Completed National Institute on Drug Abuse (NIDA) Phase 2 2001-05-01 The purpose of this study is to compare the efficacy of benztropine (or DA reuptake inhibitor) with atropine and placebo in affecting stimulated craving to cocaine cues.
NCT00001864 ↗ Amblyopia (Lazy Eye) Treatment Study Completed National Eye Institute (NEI) Phase 3 1999-05-01 The purpose of this study is to compare the results of two standard treatments for amblyopia in order to find out if one is more effective than the other. Amblyopia, which develops in childhood, is also called "lazy eye," because one eye is not being used properly. The brain favors the other eye for some reason, such as crossing or turning out of the eyes, and vision in the weak eye is reduced. Amblyopia is treated by forcing the child to use the weak eye. There are two ways to do this: 1) a patch placed over the "good" eye forces the child to use the weak eye; or 2) an eye drop placed in the "good" eye once a day to blur vision in that eye makes the child rely on the weak eye. The success rates with both of these methods have been reported to be about the same; this study will try to identify if one is more effective than the other. Children will be randomly assigned by computer to one of the following two treatment methods: Patch The child initially will wear a patch over the "good" eye for 8 to 12 hours every day. If vision in the weak eye improves, the patching time will be decreased. If vision remains good after 3 months, the patching will be stopped, unless the child's doctor believes treatment should continue. If vision in the weak eye does not improve, the patching time will be increased. Eye Drops The child will be given one drop per day of atropine in the "good" eye. If vision in the weak eye improves, the drops will be given less often. If the vision remains good after 3 months, the drops will be stopped, unless the child's doctor believes treatment should continue. If the initial daily drop does not improve the vision in the weak eye, the child's eyeglasses may be changed to try to further blur the vision in the "good" eye. After 6 months, treatment may be stopped if it has not been successful. If treatment has been successful after 6 months, it may be continued at a reduced amount or stopped. Follow-up visits will be scheduled every 4 weeks for the first 6 months and every 2 to 4 months after that until the end of the 2-year study. During each visit the eyes will be examined for eye movements and vision, and the pupils will be dilated to examine the inside of the eye.
NCT00094614 ↗ Trial Comparing Daily Atropine Versus Weekend Atropine Completed National Eye Institute (NEI) Phase 4 2002-06-01 The goals of this study are: - To compare the visual acuity outcome in the amblyopic eye after 17 weeks of daily use of atropine versus weekend-only use of atropine. - To compare the proportion of patients achieving a complete treatment response (defined as amblyopic eye acuity >20/25 or equal to that of the sound eye in the absence of a reduction in the sound eye acuity from baseline) with daily atropine versus weekend-only atropine.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Atropine

Condition Name

Condition Name for Atropine
Intervention Trials
Anesthesia 24
Myopia 23
Postoperative Pain 19
Hypotension 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Atropine
Intervention Trials
Myopia 32
Pain, Postoperative 30
Hypotension 30
Vomiting 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Atropine

Trials by Country

Trials by Country for Atropine
Location Trials
United States 91
Egypt 85
Turkey 23
China 18
Brazil 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Atropine
Location Trials
California 10
Texas 10
Maryland 9
New York 7
Ohio 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Atropine

Clinical Trial Phase

Clinical Trial Phase for Atropine
Clinical Trial Phase Trials
Phase 4 125
Phase 3 40
Phase 2/Phase 3 15
[disabled in preview] 62
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Atropine
Clinical Trial Phase Trials
Completed 194
Recruiting 54
Unknown status 47
[disabled in preview] 49
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Atropine

Sponsor Name

Sponsor Name for Atropine
Sponsor Trials
Assiut University 14
Mansoura University 13
Ain Shams University 11
[disabled in preview] 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Atropine
Sponsor Trials
Other 431
Industry 22
NIH 16
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Baxter
Boehringer Ingelheim
Dow
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.